GlassScriptPhysician profile
Diego Kuperschmit
NPI 1457450280
$25,884.86
in general payments reported to CMS, 2019-2025
44 companies · $4,513 in 2025
The $4,513 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $385 · 2021: $2,211 · 2022: $11K · 2023: $3,039 · 2024: $4,007 · 2025: $4,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,434.02 |
| Education | $125.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $7,659.13 | 2022-2025 | Omvoh |
| Abbvie INC. | $5,049.40 | 2019-2025 | |
| Janssen Biotech, INC. | $1,829.72 | 2021-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $1,415.85 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,355.43 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $934.29 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Gilead Sciences, INC. | $913.33 | 2022-2025 | Livdelzi |
| Boston Scientific Corporation | $835.73 | 2022-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Exalt Model D |
| Genzyme Corporation | $776.04 | 2022-2025 | |
| Pfizer INC. | $728.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $485.65 | 2021-2024 | |
| Madrigal Pharmaceuticals | $467.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $348.80 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $338.12 | 2019-2025 | Suflave, Sutab |
| Qol Medical, LLC | $330.25 | 2021-2025 | Sucraid |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $211.08 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $199.04 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $198.65 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $191.88 | 2022-2025 | Ibsrela |
| Olympus America INC. | $177.19 | 2023-2024 | Disposable Biopsy Forceps, Endoclot Phs, Long Clip |
| Redhill Biopharma INC. | $175.07 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Merck Sharp & Dohme LLC | $148.69 | 2021-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $142.83 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $128.72 | 2023-2025 | Zymfentra, Yuflyma, Vegzelma |
| Janssen Scientific Affairs, LLC | $121.77 | 2022 | |
| Dilon Technologies, INC. | $99.99 | 2025 | Hemoblast Bellows |
| Ironwood Pharmaceuticals, INC | $80.22 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $70.88 | 2025 | Zenpep |
| Vivus LLC | $66.67 | 2024-2025 | Pancreaze, Qsymia |
| Sandoz INC. | $59.56 | 2023-2025 | Hyrimoz |
| Organon LLC | $50.16 | 2023-2024 | Hadlima |
| Alnylam Pharmaceuticals INC. | $36.33 | 2021-2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.37 | 2023 | Cyltezo |
| Amgen INC. | $26.10 | 2024 | |
| Novo Nordisk INC | $25.46 | 2025 | Wegovy |
| Echosens North America, INC. | $25.00 | 2023 | Fibroscan |
| Ethicon US, LLC | $23.88 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.28 | 2021 | |
| Biocon Biologics INC | $22.84 | 2025 | Yesintek |
| Capsovision, INC. | $21.03 | 2024 | Capsocam Plus |
| Astrazeneca Pharmaceuticals LP | $19.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.11 | 2019 | |
| W. L. Gore & Associates, INC. | $12.49 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Kuperschmit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.